Neonatal Neoplasms
Válková J.1, Šrámková L.2, Šmelhaus V.1, Černý M.3, Kodet R.4, Švábová V.5, Cháňová M.1, Starý J.2, Koutecký J.1
Klinika dětské onkologie 2. LF UK a FN Motol, Praha1 přednosta prof. MUDr. J. Koutecký. DrSc. II. dětská klinika 2. LF UK a FN Motol, Praha2 přednosta prof. MUDr. J. Vavřinec, DrSc. Novorozenecké oddělení, Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha3 přednosta prof. MUDr. J. Hořejší, DrSc. Ústav patologie a molekulární medicíny 2. LF UK a FN Motol, Praha4 přednosta prof. MUDr. R. Kodet, CSc. Kardiocentrum, FN Motol, Praha5 přednosta MUDr. J. Škovránek, CSc. |
|
Summary:
In this report authors describe malignant neoplasms diagnosed in newborns <28 days, who were treated in the
Department of Pediatric Oncology and Haematology Section of the 2nd Department of Pediatrics, Faculty Hospital
Motol between 1990 - 2000. During this period twenty one neonates (9 boys and 12 girls) with neoplasms were
diagnosed. The histologic diagnoses were neuroblastoma (n = 11), germ cell tumor/teratoma (n = 5), retinoblastoma
(n = 2), congenital fibrosarcoma (n = 1), alveolar rhabdomyosarcoma (n = 1), acute lymphoblastic leukaemia
(n = 1). Diagnosis was established between 1 - 8 days after delivery (median 2 days). Therapy: eleven patients were
treated with surgery alone - neuroblastoma (n = 7), sacrococcygeal teratoma (n = 3), congenital fibrosarcoma
(n = 1), six patients with surgery and chemotherapy - neuroblastoma (n = 4), germ cell tumor (n = 2)). Two patients
with retinoblastoma were treated with chemotherapy and concomitant local laser therapy.Radiotherapy treatment
was necessary in two patients - disease progression (retinoblastoma) and relapse (neuroblastoma). One patient
with a relapse of germ cell tumor underwent megachemotherapy with reinfusion of autologous progenitor stem
cells. Fifteen children (71 %) are long-term survivors, two patients succumbed to the disease progression and one
patient to the toxic complications related to the treatment. Three patients (15 %) are lost to follow up. Follow up
of survivors ranges from 1 day - 134months (median 67 m.). No associated anomalies were noticed. Familiar genetic
predisposition was established in two patients with retinoblastoma.
Key words:
neonatal neoplasms, diagnosis, treatment, outcome
|